ThePeptide Examiner
Comparison

Ipamorelin vs MK-677: selective peptide vs oral small molecule, same receptor

Both activate the ghrelin receptor to stimulate growth hormone release. One's a peptide injection, the other's a daily pill. The trade-offs are bigger than the mechanism difference suggests.

Editorially reviewedThe Peptide Examiner editorial team, Editorial review · Reviewed Apr 23, 2026

Ipamorelin and MK-677 both target the growth hormone secretagogue receptor (GHSR-1a) to stimulate GH release. Ipamorelin is a synthetic pentapeptide — injection-delivered, short-duration. MK-677 (ibutamoren) is an orally bioavailable small molecule with a longer half-life that supports once-daily dosing. Neither is FDA approved. Both are on the FDA's Category 2 list.

FieldIpamorelinMK-677 (ibutamoren)
Brand namesNutrobal
ManufacturerResearch vendorsResearch vendors
FDA approvedNot FDA approved; Category 2 (Sep 2023)Not FDA approved; Category 2 (Sep 2023)
IndicationResearch: GH axis stimulationResearch: GH axis stimulation (oral)
MechanismSelective GHSR-1a agonist (peptide)GHSR-1a agonist (small molecule, oral)
DeliverySubcutaneous injection (daily or split)Oral daily tablet

Primary sources

Frequently asked

Do they produce different amounts of GH release?

MK-677 produces sustained daily GH elevation while preserving some pulsatility. Ipamorelin produces more episodic pulses matching its short half-life. Total 24-hour GH/IGF-1 exposure is typically higher with MK-677 at biohacker-typical doses.

Which has more side effects?

MK-677 reliably increases appetite (ghrelin mimicry at the same receptor), which biohackers pursuing body composition usually don't want. Ipamorelin is more selective and doesn't have the same appetite-stimulating effect. Both share the theoretical cancer-risk concerns of sustained IGF-1 elevation.

Can I stack them?

Biohacker protocols don't commonly stack them since they hit the same receptor. A more common stack is either drug paired with a GHRH analog (CJC-1295) which hits a different pathway.